Read Time: 3 minutes
Many medical treatments are designed for the average patient. But people are different, and understanding that is critical when it comes to cancer care. Precision medicine looks at variables such as genes, environments, and history to create the most effective treatment plans for patients.
Jonathan Constance, PhD, associate member in the Cell Response and Regulation Program at Huntsman Cancer Institute and assistant professor of clinical pharmacology at the University of Utah, seeks to better understand how medications can be used more safely and effectively in different patient populations, especially pediatric cancer patients.
“There are many critical knowledge gaps related to how drugs move or act,” Constance says. “The majority of drugs prescribed to children with cancer lack dosing information specific to these patients. This urgent, unmet health need results in off-label prescribing and puts these patients at risk.” Constance and his team focus on understanding factors that influence drug movement in the body, identifying early markers of drug toxicity and investigating the potential for drug-chemotherapy interactions.
“Being able to create a unique plan for each patient is the future of cancer care.”
—Jonathan Constance, PhD
Constance explains that drug dynamics in the body can be profoundly influenced by age, cancer type, and other medications. However, for most of the drugs used to treat children with cancer, population-specific data about drug movement is sparse. This prompted his team to develop a digital pharmacology platform that can be used to assess drug dynamics directly among children with cancer.
The platform is a data visualization and analysis tool that connects to a hospital’s electronic medical records to help identify blood draws that may qualify for further analysis. When a blood draw is taken that matches the researchers’ specifications, they can analyze it to help answer questions about how different drugs interact, how they impact patients with different conditions, and how long different medications stay in the blood.
“In this way,” Constance explains, “we can better understand the underlying issues concerning drug safety and efficacy, and importantly, have the data that can support optimization of drug use.”
By integrating “real-world” drug or biomarker concentration data with patient health records, researchers can perform detailed individual and population-specific studies for drug safety and efficacy.
“You really need population-specific information to understand what’s happening with the drug once the patient receives it,” Constance says.
“We are ushering in a new era as we research ways to make cancer treatment more precise and personalized.”
—Neli Ulrich, PhD, MS
While the digital tool his team created has been essential to discoveries, Constance adds that it could help answer many other critical questions in cancer care, like how to best preserve patients’ reproductive health.
“Being able to create a unique plan for each patient is the future of cancer care,” Constance says. “We are just getting started. We hope this platform will be able to aid clinicians in creating personalized treatment plans for their patients.”
“We are ushering in a new era as we research ways to make cancer treatment more precise and personalized,” says Neli Ulrich, PhD, MS, chief scientific officer and executive director of the Comprehensive Cancer Center and Jon M. and Karen Huntsman Presidential Professor in Cancer Research at the University of Utah.
In the end, it is all about finding the correct treatment plan for children with cancer. With this tool, researchers like Constance are working toward solutions.
In acknowledgement of his groundbreaking work, Constance earned recognition at the Clinical and Translational Science Awards (CTSA) meeting supported by the National Center for Advancing Translational Science (NCATS). The meeting brought together researchers from across the nation to showcase work using real-world data and artificial intelligence. Constance was also a recipient of the University of Utah’s Clinical and Translational Science Institute (CTSI) and Primary Children’s Hospital Foundation award.
About NCATS
NCATS conducts and supports research on the science and operation of translation—the process by which interventions to improve health are developed and implemented—to allow more treatments to get to more patients more quickly. It is part of the National Institutes of Health.
About CTSI
CTSI develops and applies generalizable and reproducible translational science innovations to increase the efficiency and effectiveness of research, and ultimately improve the health of our population, reducing health disparities and increasing equity. Utah CTSI serves researchers, participants, community stakeholders, and providers across our institutions, the state of Utah, and the Mountain West region.
Media Contact
Heather Simonsen
Public Affairs Senior Manager
Huntsman Cancer Institute
801 581-3194
public.affairs@hci.utah.edu
About Huntsman Cancer Institute at the University of Utah
Huntsman Cancer Institute at the University of Utah is the National Cancer Institute-designated Comprehensive Cancer Center for Utah, Idaho, Montana, Nevada, and Wyoming. With a legacy of innovative cancer research, groundbreaking discoveries, and world-class patient care, we are transforming the way cancer is understood, prevented, diagnosed, treated, and survived. Huntsman Cancer Institute focuses on delivering the most advanced cancer healing and prevention through scientific breakthroughs and cutting-edge technology to advance cancer treatments of the future beyond the standard of care today. We have more than 300 open clinical trials and 250 research teams studying cancer. More genes for inherited cancers have been discovered at Huntsman Cancer Institute than at any other cancer center. Our scientists are world-renowned for understanding how cancer begins and using that knowledge to develop innovative approaches to treat each patient’s unique disease. Huntsman Cancer Institute was founded by Jon M. and Karen Huntsman.